MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202641043042 A) filed by Skinidenticals And Innovations Private Limited, Hyderabad, Telangana, on April 3, for 'pharmacokinetically engineered diffusion controlled short contact multi-pathway retinoid delivery system for enhanced early dermal flux.'
Inventor(s) include Dr. Niharika Kadiyala.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "Pharmacokinetically Engineered Diffusion Controlled Short Contact Multi-Pathway Retinoid Delivery System for Enhanced Early Dermal Flux [00108] The present invention relates to a short-contact topical retinoid delivery system configured to enhance dermal uptake of a retinoid active agent. The system comprises a topical composition including a retinoid active agent, one or more penetration-enhancing agents, one or more surface conditioning agents, and dermatologically acceptable carriers, wherein the retinoid active agent is present in a nano-carrier system comprising a lipid-based or phospholipid-containing carrier. The composition is configured to facilitate diffusion-driven dermal delivery of the retinoid active agent within a limited duration of application. The composition comprises a retinaldehyde-containing nano-carrier composition in combination with hydroxy acids and penetration-enhancing agents in defined proportions. The system enables enhanced early-time dermal permeation during a pre-steady-state diffusion phase, thereby reducing dependence on prolonged residence of the composition on the skin surface and limiting cumulative exposure associated with irritation."
Disclaimer: Curated by HT Syndication.
